Bioniche Pharma Group Ltd., Nabi deal

Bioniche's Bioniche Teoranta unit completed its previously announced acquisition of NABI's Aloprim IV allopurinol for $3.7 million, including $1.3 million up front, $1.4 million at year end and $1 mi...